Roivant Sciences Ltd. (NASDAQ:ROIV) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Roivant Sciences Ltd. (NASDAQ:ROIV) has received a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $45.64.

A number of equities analysts have commented on ROIV shares. UBS Group set a $55.00 target price on shares of Roivant Sciences in a research note on Wednesday, September 9th. TD Cowen boosted their target price on shares of Roivant Sciences from $50.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, September 9th. HC Wainwright increased their price target on shares of Roivant Sciences from $41.00 to $47.00 and gave the company a “buy” rating in a research note on Tuesday, September 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Roivant Sciences in a report on Wednesday, August 19th. Finally, Stifel Nicolaus initiated coverage on shares of Roivant Sciences in a report on Wednesday, September 16th. They set a “buy” rating and a $51.00 price target for the company.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, Director Melissa B. Epperly sold 17,750 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $36.10, for a total transaction of $640,775.00. Following the completion of the sale, the director owned 14,954 shares of the company’s stock, valued at $539,839.40. This trade represents a 54.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mayukh Sukhatme sold 284,707 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $36.25, for a total value of $10,320,628.75. Following the sale, the insider directly owned 18,630,739 shares of the company’s stock, valued at approximately $675,364,288.75. This trade represents a 1.51% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 1,622,688 shares of company stock worth $58,826,636. Insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Roivant Sciences

Large investors have recently modified their holdings of the business. Baker BROS. Advisors LP increased its holdings in Roivant Sciences by 47.4% in the 4th quarter. Baker BROS. Advisors LP now owns 5,555,017 shares of the company’s stock valued at $120,544,000 after purchasing an additional 1,787,244 shares during the last quarter. Wellington Management Group LLP raised its position in Roivant Sciences by 179.0% in the second quarter. Wellington Management Group LLP now owns 2,687,870 shares of the company’s stock valued at $95,124,000 after purchasing an additional 1,724,588 shares during the period. Maverick Capital Ltd. acquired a new position in Roivant Sciences during the first quarter worth $45,066,000. Assenagon Asset Management S.A. lifted its stake in Roivant Sciences by 18.2% during the second quarter. Assenagon Asset Management S.A. now owns 8,362,952 shares of the company’s stock worth $295,965,000 after purchasing an additional 1,286,464 shares in the last quarter. Finally, Affinity Asset Advisors LLC boosted its position in shares of Roivant Sciences by 64.7% during the first quarter. Affinity Asset Advisors LLC now owns 2,800,000 shares of the company’s stock worth $77,560,000 after buying an additional 1,100,000 shares during the period. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Price Performance

Shares of ROIV opened at $35.44 on Wednesday. Roivant Sciences has a 52-week low of $15.90 and a 52-week high of $42.50. The company has a market capitalization of $25.60 billion, a PE ratio of -66.87 and a beta of 1.10. The stock has a fifty day simple moving average of $36.70 and a two-hundred day simple moving average of $32.86.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.04. The business had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.06 million. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. As a group, equities analysts anticipate that Roivant Sciences will post -2.00 earnings per share for the current fiscal year.

Roivant Sciences Company Profile

Roivant Sciences Ltd. (NASDAQ:ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines for patients with serious or underserved diseases. The company operates through a network of subsidiary companies, known as “Vants,” each dedicated to specific therapeutic areas, drug candidates or commercial opportunities.

Roivant’s research and development activities have included treatments for immune-mediated diseases, rare disorders, oncology and conditions affecting the nervous system.